The Starpharma Holdings Limited (ASX:SPL) share price is tumbling lower on Tuesday despite the release of a positive announcement…
The post Why the Starpharma (ASX:SPL) share price is tumbling lower today appeared first on The Motley Fool Australia. –
In afternoon trade, the dendrimer products developer’s shares are down 4.5% to $1.99.
What did Starpharma announce?
This morning Starpharma announced that its Viraleze antiviral nasal spray has now been launched in the UK by LloydsPharmacy.
Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013), which is virucidal and irreversibly inactivates >99.9% of the virus that causes COVID-19 within one minute.
The company also notes that SPL7013 has been shown to be highly active against multiple strains of COVID-19, as well as a broad spectrum of other viruses. These include influenza, RSV, SARS, MERS, and HIV.
According to the release, Viraleze is now available for purchase in the UK online at LloydsPharmacy and will soon be launched instore.
At present, LloydsPharmacy plans to rollout Viraleze to their 1,400 UK pharmacies in April. It will also be made available through McKesson’s AAH wholesale division, which services a total of 14,000 independent pharmacies in the UK.
But the company won’t be stopping there. Starpharma also plans to roll the product out across Europe, and will seek registration for the product in other regions, including Australia.
Commenting on the deal with LloydsPharmacy and McKesson last week, Starpharma’s CEO, Dr Jackie Fairley, revealed that the company was very excited with the launch.
She said: “We are excited that VIRALEZE will be available from next week in the second largest pharmacy chain in the UK. The LloydsPharmacy/McKesson team shares Starpharma’s enthusiasm and commitment to bring VIRALEZE antiviral nasal spray to UK consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”
Why is the Starpharma share price tumbling lower?
While the above is a big positive, it was already largely factored in by the market following its previous announcement.
In light of this, investors may be taking a bit of profit off the table today after a strong gain by the Starpharma share price this year.
In fact, even after today’s decline, the Starpharma share price is up 30% since the start of the year.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Starpharma (ASX:SPL) share price pushes higher on COVID-19 nasal spray update
- Why the Starpharma (ASX:SPL) share price is charging higher today
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.